Key Stats for Novo Nordisk Stock
- Price change for Novo Nordisk stock: 3%
- $NVO Share Price as of Apr. 14: $39
- 52-Week High: $81
- $NVO Stock Price Target: $47
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Novo Nordisk (NVO) stock jumped nearly 3.5% Tuesday after the company announced a new partnership with OpenAI.
- The deal is designed to help Novo analyze complex datasets, identify promising new drug candidates, and speed up the time it takes to move a medicine from early research to patients.
- CEO Mike Doustdar framed the partnership around the company’s core mission.
- He said there are millions of people living with obesity and diabetes who still need better treatment options, and AI gives Novo the ability to analyze data at a scale that was previously impossible.
- OpenAI CEO Sam Altman echoed that, calling AI a tool that can help people live better and longer lives.
- The partnership builds on Novo’s existing AI work.
- The company already has a collaboration with Nvidia, using the Gefion sovereign AI supercomputer to accelerate drug discovery.
- The OpenAI deal adds another layer to that foundation.
The timing matters.
- Novo Nordisk stock has had a rough year, down more than 25% year-to-date and sitting more than 50% below its 52-week high.
- The company is facing a tough 2026, with its own guidance pointing to an adjusted sales decline of 5% to 13% due to pricing headwinds, most-favored-nation agreements with the U.S. administration, and loss of exclusivity for semaglutide in some international markets.
At the same time, the company has strong momentum in other areas.
- Its Wegovy pill launched in the U.S. in January and hit around 170,000 users in the first month alone, which management called the fastest launch of any anti-obesity medicine in U.S. history.
- Most of those prescriptions are self-pay, suggesting strong consumer demand even without broad insurance coverage.
- A higher-dose version of Wegovy at 7.2 milligrams is also expected to receive FDA approval in the near term.
The company also has CagriSema in late-stage trials, which showed superior A1c reduction and weight loss compared to semaglutide alone in its most recent Phase III readout. And its next-generation drug, zenagamtide, is heading into Phase III trials later this year.
See analysts’ growth forecasts and price targets for Novo Nordisk stock (It’s free) >>>
What the Market Is Telling Us About Novo Nordisk Stock
Novo Nordisk stock is staging a modest recovery today amid positive sentiment around AI.
The OpenAI partnership alone won’t solve the pricing pressures the company is navigating in 2026. But it reinforces Novo’s broader strategy of using technology to stay ahead in a highly competitive obesity and diabetes market.
With Eli Lilly continuing to gain ground, Novo Nordisk’s stock needs catalysts. Today’s news is one of them.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Novo Nordisk Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
